

# Marjaana Koponen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5897169/publications.pdf>

Version: 2024-02-01

42  
papers

942  
citations

430874

18  
h-index

477307

29  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1240  
citing authors

#	ARTICLE	IF	CITATIONS
1	From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). BMC Medical Informatics and Decision Making, 2015, 15, 21.	3.0	137
2	Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer’s Disease: A National Population Cohort Study. PLoS ONE, 2014, 9, e83224.	2.5	78
3	Cohort profile: the Finnish Medication and Alzheimer’s disease (MEDALZ) study. BMJ Open, 2016, 6, e012100.	1.9	75
4	Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clinical Epidemiology, 2016, Volume 8, 363-371.	3.0	61
5	Metformin and Risk of Alzheimer’s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e963-e972.	3.6	60
6	Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease. Cmaj, 2017, 189, E519-E529.	2.0	46
7	Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors. PLoS ONE, 2015, 10, e0124500.	2.5	40
8	Trajectory Analyses of Adherence Patterns in a Real-Life Moderate to Severe Asthma Population. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1961-1969.e6.	3.8	36
9	Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease. Chest, 2016, 150, 1233-1241.	0.8	33
10	Hospital admissions, outpatient visits and healthcare costs of community-dwellers with Alzheimer’s disease. Alzheimer’s and Dementia, 2015, 11, 955-963.	0.8	30
11	Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease. Journal of the American Medical Directors Association, 2017, 18, 87.e15-87.e21.	2.5	26
12	Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer’s disease. European Neuropsychopharmacology, 2018, 28, 1260-1269.	0.7	26
13	Long-term use of antipsychotics among community-dwelling persons with Alzheimer’s disease: A nationwide register-based study. European Neuropsychopharmacology, 2015, 25, 1706-1713.	0.7	24
14	Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease. Journal of Alzheimer’s Disease, 2017, 56, 107-118.	2.6	24
15	Increased Risk of Parkinson’s Disease in Patients With Schizophrenia Spectrum Disorders. Movement Disorders, 2021, 36, 1353-1361.	3.9	23
16	Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease. Journal of Clinical Psychiatry, 2017, 78, e257-e263.	2.2	23
17	Incidence of antipsychotic use in relation to diagnosis of Alzheimer’s disease among community-dwelling persons. British Journal of Psychiatry, 2015, 207, 444-449.	2.8	22
18	Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer’s Disease. Journal of Alzheimer’s Disease, 2014, 41, 1223-1228.	2.6	19

#	ARTICLE	IF	CITATIONS
19	The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 595-602.	2.6	16
20	Application of Healthcare "Big Data"™ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN). <i>CNS Drugs</i> , 2020, 34, 897-913.	5.9	14
21	Maternal use of drugs and preeclampsia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2848-2855.	2.4	13
22	Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 711-718.	1.9	13
23	Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease. <i>Neurology</i> , 2022, 98, .	1.1	10
24	Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer's™ Disease: A Cohort Study in Finland. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 2184-2192.	3.6	9
25	Month and Season of Birth as a Risk Factor for Alzheimer's™ Disease: A Nationwide Nested Case-control Study. <i>Journal of Preventive Medicine and Public Health</i> , 2016, 49, 134-138.	1.9	9
26	Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's™ disease. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 417-425.	1.9	8
27	Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 875-882.	1.9	8
28	Causes of death in a nationwide cohort of community-dwellers with Alzheimer's™ disease. <i>BMC Geriatrics</i> , 2020, 20, 441.	2.7	7
29	Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's™ Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1243-1251.	2.6	6
30	Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1488-1494.e3.	2.5	5
31	Length of hospital stay after hip fracture and readmission rates of persons with and without Alzheimer's™ disease: a matched cohort study. <i>BMC Geriatrics</i> , 2020, 20, 214.	2.7	5
32	Does Recent Hospitalization Increase Antipsychotic Initiation Among Community Dwellers With Alzheimer's Disease?. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1543-1547.e3.	2.5	5
33	Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer's™ disease in 2005-2011. <i>PLoS ONE</i> , 2017, 12, e0173450.	2.5	5
34	Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer's™ Disease. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1059-1065.e4.	2.5	5
35	Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 751-758.	2.5	4
36	Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease. <i>International Journal of Cardiology</i> , 2020, 300, 221-225.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Coronary Revascularization and Postoperative Outcomes in People With and Without Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1524-1530.	3.6	4
38	Screening approach for identifying candidate drugs and drug-drug interactions related to hip fracture risk in persons with Alzheimer disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 875-889.	1.9	3
39	Systemic Estrogen Use and Discontinuation After Alzheimer's Disease Diagnosis in Finland 2005-2012: A Nationwide Exposure-Matched Cohort Study. <i>Drugs and Aging</i> , 2018, 35, 985-992.	2.7	3
40	Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer's Disease. <i>Clinical Epidemiology</i> , 2021, Volume 13, 295-307.	3.0	2
41	Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer's Disease: Retrospective Register-Based Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 437-445.	2.6	1
42	Automated multi-dose dispensing in persons with and without Alzheimer's disease impacts on pharmacotherapy. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 513-521.	1.9	0